Sterling Cancer & Diabetic Institute & Research Center Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 0.10 M
- Company Age 12 Year, 3 Months
- Last Filing with ROC 31 Mar 2013
- Satisfied Charges ₹ 9.50 M
About Sterling Cancer & Diabetic Institute & Research Center
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U85100MH2012PTC236663
-
Company No.
236663
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Oct 2012
-
Date of AGM
30 Sep 2013
-
Date of Balance Sheet
31 Mar 2013
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Sterling Cancer & Diabetic Institute & Research Center?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nagesh Mourya
|
Director | 10-Oct-2012 | Current |
|
Abrar Khan
|
Director | 10-Oct-2012 | Current |
|
Lalita Patil
|
Additional Director | 17-Aug-2013 | Current |
|
Umesh Warghat
|
Additional Director | 17-Aug-2013 | Current |
Financial Performance of Sterling Cancer & Diabetic Institute & Research Center.
Enhance accessibility to Sterling Cancer & Diabetic Institute & Research Center's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sterling Cancer & Diabetic Institute & Research Center?
Unlock access to Sterling Cancer & Diabetic Institute & Research Center's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Mumbai Support FoundationNagesh Mourya is a mutual person
-
Narayani Lifesciences Llp
Lalita Patil is a mutual person
-
Thane Noble Hospital Llp
Umesh Warghat is a mutual person
-
Zorgen Healthcare Private Limited
Umesh Warghat is a mutual person
Charges (Loans)
₹0
₹0.95 Cr
Charges Breakdown by Lending Institutions
- Punjab National Bank : 0.95 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Feb 2013 | Punjab National Bank | ₹9.50 M | Satisfied |
How Many Employees Work at Sterling Cancer & Diabetic Institute & Research Center?
Unlock and access historical data on people associated with Sterling Cancer & Diabetic Institute & Research Center, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sterling Cancer & Diabetic Institute & Research Center, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sterling Cancer & Diabetic Institute & Research Center's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
